Eragidomide是一种选择性Cereblon E3连接酶调节剂，通过CRL4^CRBN选择性靶向GSPT1进行泛素化和蛋白酶体降解，对癌症研究具有重要应用。

Golcadomide是一种口服有效的 CRBN E3 连接酶调节剂 (CELMoD)，通过与 CRBN 协同作用，靶向降解 Ikaros 和 Aiolos。它在非霍奇金淋巴瘤等血液肿瘤的研究和治疗中具有显著潜力。

E7820（ER68203-00）是一种口服活性芳香磺酰胺衍生物，是一种独特的血管生成抑制剂，可抑制内皮细胞上整合素α2亚基的表达。E7820以IC50为0.11 μg/ml抑制大鼠主动脉血管生成，调节α-1、α-2、α-3和α-5整合素的mRNA表达，具有抗血管生成和抗肿瘤活性。

CC-122, also known as avadomide, binds to CRBN and induces degradation of aiolos and ikaros that result in cell apoptosis. It is a antitumor and immunomodulatory agent used to treat DLBCL.

CC-220 is a modulator of cereblon that is potential to treat systemic lupus erythematosis and multiple myeloma.

Indisulam is a carbonic anhydrase inhbitor and a synthetic sulfonamide targeting the G1 phase of the cell cycle.

Tasisulam is an antitumor agent and an apoptosis inducer via the intrinsic pathway.

CC-92480 is a cereblon E3 ubiquitin ligase modulating drug (CELMoD). CC-92480 shows high affinity to cereblon, resulting in potent antimyeloma activity .

(R)-CR8 is a cyclin dependent kinase (cdk) inhibitor with IC50 of 0.036 - 0.07 and 0.09 - 0.8 μM for cdk2 and cdk1,respectively.

CC-885是一种新型的cereblon (CRBN)调节剂，其通过招募GSPT1蛋白至CRL4(CRBN) E3泛素连接酶复合物，促进GSPT1的泛素化和降解。CC-885具有在多种癌症研究中具有潜在的应用价值，特别是那些依赖于特定蛋白质稳定性的肿瘤类型。

dCeMM2 is a molecular glue degrader, inducing ubiquitination and degradation of cyclin K by prompting an interaction of CDK12:cyclin K with a CRL5B ligase complex.

dCeMM3 is a molecular glue degrader, inducing ubiquitination and degradation of cyclin K by prompting an interaction of CDK12:cyclin K with a CRL6B ligase complex.

HQ461 is a molecular glue degrader. It acts by promoting an interaction between CDK12 and DDB1-CUL4-RBX1 E3 ubiquitin ligase, leading to polyubiquitination and degradation of CDK12-interacting protein Cyclin K (CCNK).

BI-3802 is a highly potent BCL6 degrader, inhibiting the BTB domain of BCL6, with an IC50 of ≤3 nM; BI-3802 has antitumor activity.

Voclosporin (ISAtx-247) 是钙调磷酸酶 (CN; PP2B) 的抑制剂。

NRX-103094, a molecular glue, is a potent enhancer of the interaction between β-catenin, and its cognate E3 ligase, SCFβ-TrCP. NRX-103094 enhances the binding of pSer33/Ser37 β-catenin peptide for β-TrCP with an EC50 of 62 nM and a Kd of 0.6 nM.